Table 5.
Regression analyses for sex-specific obesity-related cancers in men and women*
| Variable | Men | Women | ||
| Crude HR (95% CI) |
Adjusted HR (95% CI) |
Crude HR (95% CI) |
Adjusted HR (95% CI) |
|
| BMI (per 5 kg/m2) | 0.92 (0.74 to 1.15) | 0.93 (0.75 to 1.16) | 1.22 (1.13 to 1.31) | 1.22 (1.14 to 1.32) |
| Diabetes duration (years) | 0.98 (0.95 to 1.02) | 0.98 (0.96 to 1.01) | ||
| HbA1c (mmol/mol) | 0.99 (0.98 to 1.01) | 1.00 (0.99 to 1.01) | ||
| Creatinine (µmol/L) | 1.00 (0.99 to 1.00) | 1.00 (1.00 to 1.00) | ||
| Use of metformin | 1.17 (0.85 to 1.61) | 0.86 (0.73 to 1.03) | ||
| Use of SU derivatives | 1.50 (1.07 to 2.09) | 0.93 (0.77 to 1.13) | ||
| Use of insulin | 1.34 (0.74 to 2.42) | 1.05 (0.76 to 1.44) | ||
| Smoking | 0.81 (0.55 to 1.19) | 1.00 (0.79 to 1.27) |
*In men supplemented with advanced prostate cancers (C61 +TNM 3 or 4 or Gleason score >7) (events in men: 170). In women supplemented with ovarian (ICD C56) (events in women: 39), endometrial (ICD C54.1) (events in women: 119) and postmenopausal breast cancer (ICD C50 and age ≥55 years) (events in women: 417).
BMI, body mass index; ICD, International Classification of Diseases; SU, sulfonylurea; TNM, tumour, node and metastases.